Validating Europe's De-Risked Approach

Novartis' deal on COPD compound AD 237, co-developed by Vectura and Arakis, proves that low-risk "re-profilers" can win big bucks. But the program must be right, and so must the partner's portfolio. It isn't about the technology-it's about the product.